Update on extended-release opioids in pain management

Bibliography

• Sloan PA, Barkin R. Oxymorphone and oxymorphone extended-release: a pharmacotherapeutic review. J Opioid Manag 2008;4:131-44
   PubMedGoogle Scholar
• Saunders C. The treatment of intractable pain in terminal cancer. Proc R Soc Med 1963;56:195-7
   PubMedGoogle Scholar
• Saunders CMS. The care of the terminal stages of cancer. Ann R Col Surg Engl 1967;41(Suppl):162-9
   PubMedGoogle Scholar
• Melzack R, Mount BM, Gordon JM. The Brompton mixture versus morphine solution given orally: effects on pain. Can Med Assoc J 1979;120:435-8
   PubMed Web of Science ®Google Scholar
• Thirwell MP, Sloan PA, Maroun JA, et al. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 1989;63:2275-83
   PubMed Web of Science ®Google Scholar
• Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996;11(4):203-17
   PubMed Web of Science ®Google Scholar
• Saunders C. Drugs in the treatment of the dying. Drug Ther Bull 1964;2:101-3
   Google Scholar
• Sloan PA, Babul N. Extended-release opioids for the management of chronic non-malignant pain. Exp Opin Drug Deliv 2006;3:489-97
   PubMedGoogle Scholar
• Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of Oxycontin and other opioid analgesics in The United States: 2002-2004. J Pain 2005;6(10):662-72
   PubMed Web of Science ®Google Scholar
• Shram MJ, Sathyan G, Khanna S, et al. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol 2010;30(1):25-33
   PubMed Web of Science ®Google Scholar
• Bruera E, Sloan PA, Mount BM, et al. A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. J Clin Oncol 1996;14(5):1713-17
   PubMed Web of Science ®Google Scholar
• Illgen RL, Pellino TA, Gordon DB, et al. Prospective analysis of a novel long-acting oral opioid analgesic regimen for pain control after total hip and knee arthroplasty. J Arthroplasty 2006;21(6):814-20
   PubMed Web of Science ®Google Scholar
• McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther 2001;8(3):181-6
   PubMedGoogle Scholar
• Fine PG, Mahajan G, McPherson ML. Long-acting opioids and short-acting opioids: appropriate use in chronic pain management. Pain Med 2009;10(S2):S79-88
   PubMed Web of Science ®Google Scholar
• Yoong J, Traeger LN, Gallagher ER. A pilot study to investigate adherence to long-acting opioids among patients with advanced lung cancer. J Palliat Med 2013;16(4):391-6
   PubMed Web of Science ®Google Scholar
• Eliot L, Geiser R, Loewen G. Steady-state pharmacokinetic comparison of a new, once-daily, extended-release morphine formulation (Morphelan) and OxyContin twice daily. J Oncol Pharm Pract 2001;7(1):1-8
   Google Scholar
• Brennan MJ. Update on prescription extended-release opioids and appropriate patient selection. J Multidiscip Healthc 2013;6:265-80
   PubMedGoogle Scholar
• Rauck RL. What is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical review. Pain Pract 2009;9(6):468-79
   PubMedGoogle Scholar
• Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-30
   PubMed Web of Science ®Google Scholar
• Stannard C; Chair Consensus Group. The British pain society's opioids for persistent pain: good practice. Br Pain Soc 2010;1-36
   Google Scholar
• Stambaugh JE, Reder RF, Stambaugh MD, et al. Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. J Clin Pharmacol 2001;41:500-6
   PubMed Web of Science ®Google Scholar
• Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010;CD006605
   PubMed Web of Science ®Google Scholar
• Mcllwain H, Ahdieh H. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one year study. Am J Ther 2005;12(2):106-12
   PubMedGoogle Scholar
• Rauck R, Ma T, Kerwin R, Ahdieh H. Titration with oxymorphone extended release to achieve effective long-term relief and improve tolerability in opioid-naïve patients with moderate to severe pain. Pain Med 2008;9(7):777-85
   PubMed Web of Science ®Google Scholar
• Sloan PA, Moulin D, Hays H. A clinical evaluation of TTS-Fentanyl for the treatment of cancer pain. J Pain Symptom Manage 1998;16:102-11
   PubMed Web of Science ®Google Scholar
• Tassinari D, Sartori S, Tamburini E, et al. Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials. J Palliat Care 2009;25(3):172-80
   PubMed Web of Science ®Google Scholar
• Etscheidt M, Sloan PA. Insomnia and chronic pain. In: Kaye A, Shah R, editors. Case studies in pain management. Cambridge University Press; UK: 2014; In press
   Google Scholar
• Rosenthal M, Moore P, Groves E, et al. Sleep improves when patients with chronic OA pain are managed with morning dosing of once a day extended-release morphine sulfate (AVINZA): findings from a pilot study. J Opioid Manag 2007;3:145-54
   PubMedGoogle Scholar
• Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999;26:862-9
   PubMed Web of Science ®Google Scholar
• Yue HJ, Guilleminault C. Opioid medication and sleep-disordered breathing. Med Clin North Am 2010;94:435-46
   PubMed Web of Science ®Google Scholar
• Paturi AK, Surani S, Ramar K. Sleep among opioid users. Postgrad Med 2011;123:80-7
   PubMed Web of Science ®Google Scholar
• Panagiotou I, Mystakidou K. Non-analgesic effects of opioids' effects on sleep (including sleep apnea). Curr Pharma Des 2012;18:6025-33
   PubMed Web of Science ®Google Scholar
• Prescriptions drugs: OxyContin abuse and diversion and efforts to address the problem. U.S. Government accountability office report 2004-110. Available from: www.gao/gov/products/GAO-04-110 [Last accessed 1 October 2013]
   Google Scholar
• Setnik B, Roland CL, Cleveland JM, Webster L. The abuse potential of Remoxy, and extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med 2011;12(4):618-31
   PubMed Web of Science ®Google Scholar
• Shram MJ, Sathyan G, Khanna S, et al. Evaluation of the abuse potential of extended-release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol 2010;30(1):25-33
   PubMed Web of Science ®Google Scholar
• Wilsey BL, Fishman S, Li CS, et al. Markers of abuse liability of short-vs long-acting opioids in chronic pain patients: a randomized cross-over trial. Pharmacol Biochem Behav 2009;94(1):98-107
   PubMed Web of Science ®Google Scholar
• Kirsh K, Peppin J, Coleman J. Characterization of prescription opioid abuse in the United States: focus on route of administration. J Pain Palliat Care Pharmacother 2012;26(4):348-61
   PubMedGoogle Scholar
• Cicero TJ, Surratt H, Inciardi JA, Munoz A. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol Drug Saf 2007;16(8):827-40
   PubMed Web of Science ®Google Scholar
• Benedek IH, Jobes J, Xiang Q, Fiske WD. Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. Drug Des Devel Ther 2011;5:455-63
   PubMed Web of Science ®Google Scholar